The U.K.’s medicines regulator approved Eli Lilly’s weight-loss pill on Monday, marking a first European license for the company’s drug.

The Medicines and Healthcare products Regulatory Agency authorized Foundayo (orforglipron) for weight management and type 2 diabetes, and is the “first regulator in Europe” to approve the drug. In the EU, a decision is not expected until next year.

Foundayo is Lilly’s first oral form of the popular GLP-1 drug class, which has surged in popularity with demand fueled by the backing of celebrities and influencers. Its injectable drug Mounjaro (tirzepatide) had been riding this wave.